The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Marine Gross-Goupil
Consulting or Advisory Role - Amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; ipsen; MSD Oncology; Roche; Roche; Roche
 
Jeffrey C. Goh
Stock and Other Ownership Interests - Immutep
Consulting or Advisory Role - AstraZeneca; Tesaro
Speakers' Bureau - Ipsen; Janssen; Mundipharma; Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Ronald De Wit
Honoraria - Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Bayer; Clovis Oncology; Janssen; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Lilly
 
Tuomo Alanko
Consulting or Advisory Role - Amgen; Baxalta/Shire; Bayer; Bristol-Myers Squibb; Celgene; Kaiku Health; Lilly; MSD; Nordic Drugs; Roche
Research Funding - AbbVie (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Baxalta/Shire; Bristol-Myers Squibb; MSD; Pfizer; Roche
 
Satoshi Fukasawa
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb Japan; Daiichi Sankyo; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca
 
Kenichi Tabata
No Relationships to Disclose
 
Susan Feyerabend
No Relationships to Disclose
 
Raanan Berger
Stock and Other Ownership Interests - Belong; Mitra Biotech
Honoraria - AstraZeneca; Bristol-Myers Squibb; Mitra Biotech; MSD; Pfizer; Roche Israel
Consulting or Advisory Role - Belong; Bristol-Myers Squibb; Mitra Biotech; MSD Oncology
Speakers' Bureau - Bristol-Myers Squibb; Mitra Biotech; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Mitra Biotech; MSD
 
Helen Wu
Employment - MSD
Stock and Other Ownership Interests - Merck Sharp & Dohme (I)
Travel, Accommodations, Expenses - MSD RD China
 
Jeri Kim
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex